Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart

Gaetano Santulli; Fahimeh Varzideh; Imma Forzano; Scott Wilson; Luigi Salemme; Antonio De Donato; Angela Lombardi; Antonio Rainone; Luigi Nunziata; Stanislovas S. Jankauskas; Tullio Tesorio; Germano Guerra; Urna Kansakar; Pasquale Mone

doi:10.1161/HYPERTENSIONAHA.123.20598

Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart

Gaetano Santulli, Fahimeh Varzideh, Imma Forzano, Scott Wilson, Luigi Salemme, Antonio De Donato, Angela Lombardi, Antonio Rainone, Luigi Nunziata, Stanislovas S. Jankauskas, Tullio Tesorio, Germano Guerra, Urna Kansakar, Pasquale Mone

Medicine

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty.

Original language	English (US)
Pages (from-to)	1800-1809
Number of pages	10
Journal	Hypertension
Volume	80
Issue number	9
DOIs	https://doi.org/10.1161/HYPERTENSIONAHA.123.20598
State	Published - Sep 1 2023

Keywords

cardiology
endocrinology
frailty
geriatrics
metabolism
nephrology
pharmacology

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1161/HYPERTENSIONAHA.123.20598

Cite this

Santulli, G., Varzideh, F., Forzano, I., Wilson, S., Salemme, L., De Donato, A., Lombardi, A., Rainone, A., Nunziata, L., Jankauskas, S. S., Tesorio, T., Guerra, G., Kansakar, U., & Mone, P. (2023). Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart. Hypertension, 80(9), 1800-1809. https://doi.org/10.1161/HYPERTENSIONAHA.123.20598

Santulli, G, Varzideh, F, Forzano, I, Wilson, S, Salemme, L, De Donato, A, Lombardi, A, Rainone, A, Nunziata, L, Jankauskas, SS, Tesorio, T, Guerra, G, Kansakar, U & Mone, P 2023, 'Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart', Hypertension, vol. 80, no. 9, pp. 1800-1809. https://doi.org/10.1161/HYPERTENSIONAHA.123.20598

@article{3ca0d6a240f04c049612f51909e3dbef,

title = "Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart",

abstract = "SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty.",

keywords = "cardiology, endocrinology, frailty, geriatrics, metabolism, nephrology, pharmacology",

author = "Gaetano Santulli and Fahimeh Varzideh and Imma Forzano and Scott Wilson and Luigi Salemme and {De Donato}, Antonio and Angela Lombardi and Antonio Rainone and Luigi Nunziata and Jankauskas, {Stanislovas S.} and Tullio Tesorio and Germano Guerra and Urna Kansakar and Pasquale Mone",

year = "2023",

month = sep,

day = "1",

doi = "10.1161/HYPERTENSIONAHA.123.20598",

language = "English (US)",

volume = "80",

pages = "1800--1809",

journal = "Hypertension",

issn = "0194-911X",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - Functional and Clinical Importance of SGLT2-inhibitors in Frailty

T2 - From the Kidney to the Heart

AU - Santulli, Gaetano

AU - Varzideh, Fahimeh

AU - Forzano, Imma

AU - Wilson, Scott

AU - Salemme, Luigi

AU - De Donato, Antonio

AU - Lombardi, Angela

AU - Rainone, Antonio

AU - Nunziata, Luigi

AU - Jankauskas, Stanislovas S.

AU - Tesorio, Tullio

AU - Guerra, Germano

AU - Kansakar, Urna

AU - Mone, Pasquale

PY - 2023/9/1

Y1 - 2023/9/1

N2 - SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty.

AB - SGLT2 (sodium-glucose cotransporter 2) enables glucose and sodium reabsorption in the kidney. SGLT2-inhibitors (also known as gliflozins, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) act by increasing glycosuria, thereby reducing glycemia. These drugs are critical to reach and keep glycemic control, a crucial feature, especially in patients with comorbidities, like frail individuals. Several studies evaluated the effects of SGLT2-inhibitors in different settings beyond diabetes, revealing that they are actually pleiotropic drugs. We recently evidenced the favorable effects of SGLT2-inhibition on physical and cognitive impairment in frail older adults with diabetes and hypertension. In the present overview, we summarize the latest clinical and preclinical studies exploring the main effects of SGLT2-inhibitors on kidney and heart, emphasizing their potential beneficial actions in frailty.

KW - cardiology

KW - endocrinology

KW - frailty

KW - geriatrics

KW - metabolism

KW - nephrology

KW - pharmacology

UR - http://www.scopus.com/inward/record.url?scp=85168235156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168235156&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.123.20598

DO - 10.1161/HYPERTENSIONAHA.123.20598

M3 - Review article

C2 - 37403685

AN - SCOPUS:85168235156

SN - 0194-911X

VL - 80

SP - 1800

EP - 1809

JO - Hypertension

JF - Hypertension

IS - 9

ER -

Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this